Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Herantis Pharma phase 1b data readout

By Inderes10/8/2025, 10:00 AM
Herantis Pharma
Investor events

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:00 - 34:26

Warm welcome to this pharma webcast, where we'll present Her 96 Phase 1B clinical trials. Topline data. We will present the data. And this presentation is followed by a Q&A session. During the webcast, please enter your questions in the dashboard. And let's start. And my name is Antti. I'm the CEO of the company. And together with me in the studio, we have our CSO Henry Huttunen and CFO Nicole. And before going into the actual presentation, just a reminder of forward-looking statements is necessary. And then we can actually start the webcast content. Just a reminder, at This Pharma, we are a clinical-stage public company residing here in Helsinki. And we are developing Her 96 as our lead asset. And that is a potentially game-changing therapy that can become the first disease-modifying and neurorestorative treatment for Parkinson's disease. Short recap about the background. So Her 96 is a mimic of a protein called cerebral dopamine neurotrophic factor CDNF. Previously, we have studied CDNF in pre-clinical and clinical studies with very promising results. And the challenge with CDNF protein was the route of administration. But with Her 96, we have exactly the same mechanism of action and same activity. But we can use simple, patient-friendly subcutaneous administration. And of course, now we are in the webcast to present the phase one B topline data. So, very happy to announce that we have met. Now the trial has met the primary and secondary endpoints for safety and tolerability. And this data, of course, strongly supports advancing Her 96 into phase two. Proof of concept clinical trials. We expect further data by releasing the full data set, including the biomarker data, before the end of 2025. Just a reminder that there is a high unmet clinical need in Parkinson's disease. The current treatments can alleviate the symptoms, but as of now, nothing can prevent the progression of the disease. And this is exactly what we want to do: stop the progression of the disease at the early stage. And of course, we want to also be a strong player in the rapidly growing market for pharmaceuticals for Parkinson's disease. I just want to remind you about the phase one objective. So clinical development, or drug development, is divided into nonclinical development and clinical development. We have received very compelling data from preclinical studies showing the proof of concept of N96 as described earlier. We have previously conducted a phase one clinical study to demonstrate the safety and pharmacokinetics in healthy volunteers. And now we are pleased to announce the excellent data from phase one. This study has established safety and pharmacokinetics in Parkinson's patients, and also determined dosing for phase two. But let us continue with the actual presentation of the data by our CSO, Henry Huttunen. So please. Thank you, Auntie. So let's begin by the study design. So the study was divided into two parts. There was a brief part one where we studied elderly healthy volunteers, who received a single subcutaneous dose of 300mg of n96. The purpose of this was to study the safety of the higher dose in elderly individuals and also to extend the cerebrospinal fluid pharmacokinetic data to later time points to complement our previous phase one PK data set. This was completed last autumn, and we briefly reported this Part One data on November 24th. Now the main part of the study was part two, where we recruited 24 subjects with Parkinson's disease, divided into two cohorts, 12 subjects each. The two cohorts received either 200 or 300mg doses of N96 subcutaneously, two injections per week for four weeks. Each of these two cohorts had four placebo subjects and eight subjects receiving the active drug. So this was a repeated dosing study. The primary endpoint of the study was to assess the safety and tolerability of repeated dosing of her 96 in Parkinson's patients, and the secondary endpoint related to the pharmacokinetics of repeated dosing. We are also conducting extensive exploratory biomarker work related to the phase one study, focusing on assessing the biological response to treatment. Now, for part one, which involved aged healthy individuals receiving a single dose, we recruited individuals aged between 50 to 75. The main key inclusion exclusion criteria are fairly simple, fairly standard phase one criteria except for the age range. The part two. Key inclusion and exclusion criteria are a little bit more extensive. And here are listed the most important ones. Importantly, the subjects had to have a clinically established diagnosis of early idiopathic Parkinson's disease, staged with a modified Hoehn and Yahr scale up to 2.5, with akinesia and one of the other cardinal signs, without any other known or suspected cause of Parkinson's. Also, all subjects had a brain dopamine transporter SPECT or PET imaging result, and the purpose of this was to confirm the dopaminergic deficit. To confirm the Parkinson's diagnosis. Patients were required to have a stable clinical disease state with either no current symptomatic medication or stable treatment, including either levodopa, dopamine agonists, or monoamine oxidase B inhibitor. If you look at the exclusion criteria, there are a few important ones: history or current clinically significant medical conditions, including cancer, major psychiatric disorders, or other neurological disorders besides Parkinson's. Also, if there were indications in the brain MRI of a clinically significant brain pathology, the patient had to be excluded from the study. Also, there were exclusion criteria related to late stage Parkinson's phenomena, such as wearing off dyskinesia, or if the subjects weren't allowed to be on apomorphine infusions, for example, or deep brain stimulation. So just to understand the basic characteristics of our patients who were allowed to enter this study. Now, this study was conducted at two clinical sites in Finland, one site in Turku and one site located in Helsinki. This was operated by our clinical CRO partner, CRC, and part one was conducted between September and November last year. Part two started very late this year, and the last patient's last visit took place in mid-August. Overall, we can say that the study was conducted within the anticipated timelines and budget. So as a company, we are, of course, very happy with such performance. Now here's the summary of demographic data, basically summarizing age, race, sex, and body mass index. As you can see, there is no significant difference between the groups, particularly in part two. Nothing noteworthy here. And if we look at part two, the repeated dosing in Parkinson's patients, you can see some characteristics of the disease here. The modified Hoehn and Yahr scale is the typical scale for describing the stage of the disease, and as mentioned with the inclusion and exclusion criteria, 2.5 was set as the highest allowed stage. There's a little bit of imbalance in distribution, which is typical for a small randomized clinical study. For example, here we can see that both placebo and 200mg groups have perhaps more subjects who are stage 1 and 1.5, compared to the 300mg group that has more patients relatively at stage 2 or 2.5. In general, this is not unusual. It's just good to keep in mind when going through the data. Now, the UPDRS is the Unified Parkinson's Disease Rating Scale. It is a scoring system to describe the patient's state and severity of symptoms. Part three is a clinician assessment particularly focusing on the motor symptoms. And as you can see here, the groups were fairly evenly distributed in terms of the UPDRS. The UPDRS total score includes part two. So the clinician assessment, on top of that, also includes some patient-reported parameters like time from diagnosis and time from first symptoms, which are also listed here. You can get an idea of the average duration of the disease in these subjects, which is fairly evenly distributed among the groups. As mentioned, the patients were allowed to use symptomatic Parkinson's medication. And here's a table summarizing the medication use. All patients used 1 to 3 symptomatic medications. The dopamine agonists, Dopa levodopa, and monoamine oxidase B inhibitors are all related to maintaining and increasing the dopamine level in the brain. They operate slightly differently, but they share the same principle of alleviating motor symptoms by restoring dopamine levels. Beta blockers are not necessarily Parkinson's medications. They can sometimes be used to control peripheral adrenergic activity, which may help in the control of tremor amplitude, for example. Now, conclusions on part one, the single 300mg dose: the safety data overall was well aligned with our previously reported phase one data. There was nothing unusual. The subjects displayed very similar injection site reactions. There was nothing in systemic adverse events. The pharmacokinetic data was as expected, so we will continue with the rest of the presentation. Today we will focus on part two. The repeated dosing in patients. This table summarizes the adverse events in part two. So overall, you can see on the top line a summary of any adverse events. Then a breakdown for treatment-emergent adverse events. Suspected drug-related treatment emergent adverse events, severe adverse treatment emergent adverse events, and any serious adverse events. So this is a typical way to categorize different types of adverse events in clinical trials. Overall, we can say that there was only one serious adverse event. This was in the placebo group. It was noted at a very late stage. So basically, at the end of the follow-up period, we can conclude that this serious adverse event, which was a bladder neoplasm, had nothing to do with HER96 because the patient was never exposed to the drug. Overall, there are slightly more adverse events in the higher dose group. Overall, all patients reported at least some adverse events in all of these groups except in the placebo, where there were only seven out of eight reporting AES. So this gives an overview of the safety data. In general, it is important to emphasize that the majority of these adverse events were related to the injection site. So there were very few systemic adverse events. Nothing noteworthy, which is also well aligned with our previously reported phase 1a data. Safety laboratory results on blood and urine, hematology, clinical chemistry assessment, and so on. All samples. All results remained within normal limits throughout the study. So there were no trends or abnormalities that would indicate any safety concerns. And this is again well aligned with the rest of the safety data. Also, the brain MRI results. The brain MRI was done at screening and at the end of the study visit. The overall conclusion from the imaging data was that there were no findings suggesting any changes related to this study. Now, if we take a closer look at the injection site reactions, which you may remember are where the majority of the adverse events occur in total. Now, these are all very typical injection site reactions. Pain, bruising, erythema. Anybody who has ever received a vaccination can imagine that it stings a little bit. There's a little bit of bruising and perhaps a little bit of redness, erythema, on the skin. So this is what we also see with the injections of HER-96 in general. And importantly, the injection site reactions were mostly mild and they were transient. So, in conclusion, we can say that this is again in line with our phase one data and our preclinical toxicology data. And it is very much expected to see these types of injection site reactions with an injectable product. Another important safety assessment for peptides and biological drugs is the assessment of anti-drug antibodies. So here we collected samples at predose. So before the first dose and at the end of the study visit. So we had altogether 48 samples. And three of these samples in the anti-drug antibody assays were confirmed positive. However, it should be noted that two of these three samples were in the placebo group. There was one subject whose pre-dose and end-of-study samples both showed a positive signal. This may be just coincidental, and it's quite typical for this type of assays. The only sample that was positive in the groups receiving her 96 was also a pre-dose sample. So in conclusion, we can say that there was no evidence in this study of anti-drug antibody formation in subjects who received repeated dosing of Her 96 for 28 days. Now, moving on from general safety to Parkinson's symptoms. So we included the Unified Parkinson's Disease Rating Scale (UPDRS) in the study for safety purposes. And the conclusion is very clear. There was no change at the group level in the UPDRS. Part II scores. The motor symptoms in these patients receiving HER-96 or placebo remained stable throughout the study. Any further interpretations of motor symptom data are very much limited by the short treatment time and follow-up time. Also, the small sample size. So I would like to emphasize that this study was not designed or powered to draw any efficacy conclusions. Related to motor symptoms. We also included a digital health technology tool. Parkinson's kinetic graph, a wrist-worn smartwatch-like device that continuously collects information on motor features. The purpose of this was to enrich the dataset and learn how to implement these novel technologies in clinical studies. As we anticipate moving to a phase two study, hopefully soon in the near future. In this study, we have not completed the analysis of the digital biomarker data yet. We have done a preliminary analysis in-house focusing on the 50 score, which is shown in this graph and aligned with the UPDRS score. The 50 score does not show any changes in the weekly averages, which are the individual data points in this graph. The full analysis of the digital biomarker data is ongoing with the partner. And we will be reporting this data together with the rest of the biomarker data by the end of the year. So conclusions on safety for the repeated dosing part. This study clearly demonstrated a good safety profile for both single and repeated doses of 200mg and 300mg per 9696, which was safe and well tolerated in Parkinson's patients. Importantly, all participants completed the study without disruptions, including unproblematic subcutaneous injections twice weekly for one month. The safety labs and brain MRIs did not suggest any findings in the safety data set. Overall, the adverse event profile for 96 was good and aligned with our expectations based on previous studies. And the one related serious adverse event that was reported in the study was in the placebo group and clearly not related to her 96 exposure. There was also no evidence of antidrug antibody formation in subjects during this one-month dosing period, which is an important complementary part of the safety data set. The local reactions related to the injection were very common. They were observed both in active and placebo groups, and in general, they were mild and transient. Now, let's move on to the pharmacokinetic data. So these graphs show the plasma pharmacokinetic data at the time-concentration curves after the first dose and after the last dose. Uh, left and right. So what we can conclude from these data is that, first of all, these profiles are very much aligned with the PK profile seen after a single dose in healthy volunteers in the phase one study. It is very well aligned with our preclinical pharmacokinetic data. And there's no accumulation after repeated dosing. Perhaps it's good to remind when looking at these curves that this PK profile is well matched with the planned intermittent dosing regimen. As Hernandez has a hit-and-run mechanism of action. Cerebrospinal fluid samples were collected both for biomarker purposes and to further understand the pharmacokinetics. Properties of Hernandez 6 and this graph on the left shows samples that were collected eight hours after the last dose in part two. So, you can see that, first of all, there is very clearly the presence of Her 96 in the cerebrospinal fluid in all subjects. Uh, it's very much in the expected concentration range. The average in the 200mg group is around 80 nanograms per milliliter and in the 300mg cohort, around 140 nanograms per milliliter. The slightly wider distribution in the 300mg group is most likely explained by body size differences. The graph on the right shows a correlation analysis of total plasma exposure area under the curve on the y-axis and then the CSF levels. The single timepoint CSF levels. On the x-axis, we have a high correlation. The R square being around 0.6. Overall, we are very happy with these results. These results together with our previous phase one A data and the part one data from this study show that 200 to 300mg doses of 96 result in cerebrospinal fluid levels that are expected in the pharmacologically active level and very much aligned with our preclinical data. Now, if we put together a cross-sectional aggregate of the CSF data. By pulling together the Phase One A healthy volunteer data and Phase One B healthy volunteer data, we can now get a temporal view on the distribution of the data points. This doesn't allow us a full pharmacokinetic parameter determination as these are single time point samples per subject. This is not serial sampling. However, this allows and gives us a very good overview of how quickly her 96 reaches the cerebrospinal fluid compartment, and what is the elimination half-life from the CSF. And here, we can conclude based on this data that the CSF Tmax lies at around 8 to 16 hours and the CSF half-life is approximately six hours. And this is again well aligned with the predicted elimination rate in humans. And it supports dosing in phase two twice weekly. Now, overall, we can conclude that the primary and secondary objectives of the phase one study were met. Her 96 is safe and well tolerated in Parkinson's disease patients. Overall, the phase one study was conducted efficiently within anticipated timelines and budget. and pulled together. The phase one and phase one B data strongly support advancing her 96 into the phase two trial to assess efficacy. Now, the topline data that we're reporting here today doesn't cover all the data from this phase one B study, as we've indicated before and in yesterday's release as well, there's still data to come towards the end of the year. And this data relates to biomarkers. So now with this data, we can check three very important boxes. The safety and the pharmacokinetics. We have also established the dosing level and dosing frequency for phase two. But we still have one box to tick. And we are working very hard to get this data together by the end of the year. And biomarkers can mean a lot of things. So what do we actually mean by biomarkers? What are we expecting from this data set? Overall, in general. Biomarkers are measurable biological indicators that reflect drug action or, alternatively, disease state. They have become a critical element of modern drug development. Modern clinical trials. They can help to confirm proof of mechanism and target engagement. They can show a biological effect before clinical outcomes appear. Guide dose selection, identify responders and non-responders, overall reduce time, cost, and risk of failure, and particularly from the partnering point of view, this is very important. This allows us to make better informed go/no-go decisions and helps to de-risk programs by us or our partners. It helps us to design smaller, faster, more informative clinical trials and make smarter and faster transitions to the next phase. So Parkinson's disease is a heterogeneous disease. Every subject has a slightly different variation of the disease. The underlying biology is not the same among the patients. That's why it's critically important that we understand this biological background, and we are collecting information related to genetic background and genetic risk. We're collecting a large number of fluid samples, blood, cerebrospinal fluid. That would help us to understand the differences between patients. However, this is only one part. The more important part relates to biological response. And this is typically a key question for phase one studies. Can you provide any information, any data that would demonstrate that the human body responds in an expected way to exposure to the drug? Biological response can mean many things. It can mean safety-related aspects. It can mean symptom monitoring. But particularly important for us is the pharmacodynamic component. So this means how the human body responds to the drug. Particularly in phase one studies, the demonstration of target engagement, target pathway modulation, and proof of mechanism can serve as very important go/no-go decisions. It can create tremendous value for the program to be able to demonstrate this. There are also, of course, questions related to disease modification. This might be a question more suited for phase two, particularly because the study we are conducting is relatively short in duration. But the pharmacodynamic aspects are particularly important for our 96 program, because we are working with a target mechanism that is fairly new to clinical drug development. We need to pioneer. We need to produce the data. And that's why phase one B will focus on the pharmacodynamic biological response to the treatment. All this data is expected by the end of the year. And hopefully, the digital biomarker data set will be fully analyzed and reported by that time. Thank you, Henry, for taking us through the great top line data that we released yesterday evening. This was the sponsor of the study, but of course, we have not been alone. Being able to achieve this data. So basically, we would like to thank the healthy volunteers and, of course, the Parkinson's patients and their families. Without you, this could not have been possible. In addition to the patients and healthy volunteers, there has been a vast network of partners and suppliers that we have worked with. I would like to highlight the Crest team as a clinical site to enable this clinical study. But of course, there are other persons as well in analytical labs and CROs and other types of organizations as well. Significant support and achievements have been made, and thanks go to you as well. But I also want to highlight our own team. As Henry already mentioned, we conducted this study within the preset timeline and within the budget. And it is a great achievement from this team. And it really shows that we can deliver with this development program. Of course, investors and financing are crucial parts of taking drug development forward. And I would like to especially provide my thanks to patient organizations that have supported us financially, enabling this study. So the Michael J. Fox Foundation and the Parkinson's UK, providing us the great financial support for the phase one B and biomarker program, but also being there and helping us in other aspects as well. The Michael J. Fox Foundation and Parkinson's UK provided us with great financial support for the Phase 1B and biomarker program, but also assisted us in other aspects as well. So as a summary, we achieved great data with phase one. We achieved great data with phase one B, as the study met the primary and secondary objectives. So we have great safety data. We have expected pharmacokinetic data. We have confirmed the dosing for phase two. So we have all the motivation and the foundation to proceed with the program to phase two efficacy trial. And, of course, the company is currently preparing for that study. At the same time, we are completing the phase one biomarker studies and reporting that by the end of the year. And of course, being able to release the top-line data now helps us to continue the partnering discussions. And we will have a very busy autumn, being in contact with potential pharma partners with one-to-one meetings and participating in different partnering events. And that's, of course, the ambition of the company, as we have communicated many times before, that we would like to have a partner on board when we go into phase two. So that's, of course, the emphasis of the company and the management team to enable that to happen. I think we have now completed the webcast in terms of the data review. And now it's time for the Q&A. And our CFO, Nicola, will come here and host the Q&A session with us.

Nicola
34:27 - 34:41

And of course, being able to release the top line data now helps us to continue the partnering discussions. We have many viewers today and a lot of exciting questions, so be prepared. Why will it take 2 to 3 months until the full data set will be reported?

Unknown 1
34:41 - 36:00

Yes, this is a very good question. And there are actually several layers explaining that. One is that we have collected a large number of samples, different matrices, blood, CSF, and so on. These are analyzed with different technologies from various technology providers and service providers globally. Some of these providers have a certain lead time. They cannot deliver the data. The next day after you send the samples in, it is not immediately possible to receive the data. So it takes a little while to run these analyses. But even when that's completed, we are only halfway through. The data analysis can actually be very complex too, because we have several omics data sets. We're looking at proteomics data; for example, one proteomic study could have hundreds of thousands of data points. We have multiple time points, 24 patient groups, and more than 10,000 analytes in each sample. So all that provides a very, very rich body of data, and that requires quite extensive and advanced bioinformatic analysis. And integrating all that data together with the clinical data is quite time-consuming. Yes.

Nicola
36:01 - 36:13

Looking ahead to phase two, what will the trial design look like and do you anticipate it being an international study? And how many patients do you expect to enroll?

Unknown 1
36:15 - 37:13

Well, first of all, we expect it to be an international study. Our current view is that the study would be run in Europe across several countries. We have started discussions with potential investigators and sites. There are a few that we're already deeper in the discussion, so we have some idea of how and where it could be run. It is a little bit premature to speculate on the details of the study design. There are several elements that still need to be decided. We're discussing and planning internally together with our advisors. Things related to study duration, number of patients, and which endpoints will be selected. That also depends a little bit on our full data set on Phase 1B. Therefore. So at this stage, we're not ready to provide further details on the phase two design.

Nicola
37:14 - 37:26

Yeah. How much funding is required and how will you fund the phase two study? What are your plans to raise additional funding?

Unknown 1
37:26 - 38:24

Yeah. So of course, the data that we release now gives a strong rationale for running the phase two. And as Henry already mentioned, we have been planning for phase two. However, for finalizing the phase two plans, we need to have the biomarker data analyzed and interpreted. However, if we just look at it in general, the industry phase two proof of concept study might cost somewhere around €15 to €20 million. We are currently looking at different options for how we could resource that kind of study. Of course, we are looking at partnering. We are looking at potential equity financing. We are also looking at potential grant financing. And of course, when the time comes, we will have more information about how to practically set up the phase two.

Nicola
38:26 - 38:37

There is a lot of interest in disease-modifying therapies for Parkinson's. How is her 96 different from other approaches in development?

Unknown 1
38:39 - 39:25

That's a very good question. Her 96. First of all, it is the first of its kind treatment targeting the unfolded protein response pathway in Parkinson's or in any neurodegenerative disease. So just based on the mechanism of action, it already differs from many other approaches. We also believe that this is a quite unique combination of neuroprotection, restoration of proteostasis, anti-inflammatory effects, and also the ability to promote functional recovery of stressed neurons. This, we believe, is the package that makes HER96 stand out among its peers.

Nicola
39:26 - 39:57

Good. So, more related to the funding. What kind of funding structure would you prefer if you need additional funding? Is it partnering? Is it more non-dilutive funding from Michael J. Fox and Parkinson's UK, and how do you look into the funding opportunity that you still have with the equity which is not spent?

Unknown 1
39:59 - 41:20

Yeah. So basically, if we start with partnering, of course, as we have communicated and already mentioned, the ambition is to find the right partner. Of course, with the We also need to think about what kind of potential partnering deal we might sign or what the terms could be, which we don't know and can't comment on right now. So it really depends on that. We are definitely looking at different kinds of non-dilutive grant-type funding opportunities. However, of course, those are something that we can't comment on right now. EIC is a very strong support for us. And just a reminder that we still have approximately €12 million there in their pre-commitment, which they are able to finance up to one third of any equity financing round if we choose to go that route. As already mentioned, now is the time to look at the different options to see, and then later on we will select what would be optimal. choice for the company and supporting phase two and further growth.

Nicola
41:21 - 41:40

Good. So more questions related to biomarkers. What are your hopes and expectations regarding the results of the biomarker measurements? Will there be anything that hints towards slowing the disease progression?

Unknown 1
41:42 - 43:12

Well, as already pointed out in the presentation, emphasis is largely on the proof of mechanism, pharmacodynamic target pathway, and modulation type of responses. We do have a set of targeted biomarkers, which means pre-selected biomarkers based on certain criteria, but also a broad approach using untargeted approaches, including proteomics, for example. There are different ways you can expect to see results here. So you could see changes in individual targeted markers, or perhaps more on the pathway level in the omics data. For example, the unfolded protein response pathway is strongly connected to the regulation of gene expression. So we would expect to see something on a pathway level related to proteomics data, specifically how certain protein markers are changing broadly, not just a single marker, but broadly. Regarding time, the study is still quite short. It is only 28 days. It is a little bit hard to speculate which disease modification-associated biomarkers would show a clear change in such a short time. So I think we'll just need to keep an open mind and see what the data tells us. This.

Nicola
43:14 - 43:18

Which biomarkers were monitored in the study?

Unknown 1
43:18 - 43:30

It is a very, very large group of biomarkers. I don't want to name a single marker here because we're using a very broad combination of targeted and untargeted approaches. Yes.

Nicola
43:30 - 43:41

Congratulations. With the positive phase one results. Although not designed for efficacy, were there any exploratory trends that might hint at early efficacy signals?

Unknown 1
43:44 - 44:32

Well, the UPDRS and the PPG-50 data available today at the group level don't indicate anything. And this is exactly what we expected from such a small study that's not powered for assessing efficacy. It is, of course, possible. Never say never. When you dive deeper into the data, you explore complex biomarker data. You never know what you can discover there. But I would again remind that the short duration of the study and the small number of patients is limiting any further speculations on symptom improvement at this stage.

Nicola
44:34 - 44:46

Were there any differences in the type of adverse events, tolerability, or drug exposure between the 200mg and the 300mg cohorts other than injection site reactions?

Unknown 1
44:47 - 45:19

Not really. The number of AEs was slightly higher with the 300mg group. This may simply relate to the slightly higher dosing volume. The drug concentration in the drug product was the same, so when we increased the dose, we had to increase the injection volume, which per se can increase injection site reactions, but broadly speaking, there's nothing noteworthy between the two groups.

Nicola
45:19 - 45:29

Okay, so back to the phase two study again. What are the main regulatory, logistical, and financial steps required before you can start a phase two?

Unknown 1
45:30 - 46:33

Maybe I will start with that. Of course, when setting up a clinical study, we need to have enough resources for the preparation of the study and applying for the clinical trial authorization. And then, of course, we need to have enough financial resources to actually run the study. And of course, as already mentioned, we are looking at different options for resourcing the study. Related to. The actual study setup. Currently it seems like it should be pretty straightforward with those plans that we have already created, and we have preliminarily assessed the regulatory paths and everything related to the investigational drug and such things. So we believe that it should be a rather straightforward program to set up the study and practically conduct it if we have the right resources in place.

Nicola
46:34 - 46:43

Okay. Based on animal models and testing, is it possible to estimate after how long treatment the clinical symptoms could show change?

Unknown 1
46:47 - 48:38

Well, mice are not very good humans. So, preclinical models, their translatability to the human disease setting is always complicated. So, it is a very difficult question to give a straightforward answer to. I believe. We don't have many hours to sit here listening to me speculate on that. We can look at some other studies, for example, studies done with an alpha-synuclein antibody, trastuzumab, the Padova study, and Pasadena study, that were conducted by Roche. They said in their recent presentations that one year is a realistic time frame to expect. With that mechanism of action. It might be slightly different. If you have a passive supportive mechanism removing alpha-synuclein compared to an active neuronal functional recovery-promoting compound like 96. So the time frame could be different. So, I think time will tell. And when we're ready, we will come out with the phase two design. And I can guarantee that we have spent a lot of time discussing this timing question with our advisors and team. So we will be confident about the decision, and maybe I can continue with that. Also, the biomarker data that we are looking at might give us more insight into this time perspective for the phase two.

Nicola
48:40 - 48:49

Related to the biomarker plan, is genetic diagnosis included as a prerequisite for the Hero 96 therapy?

Unknown 1
48:50 - 49:30

There is no basis for that right now. We included genetic characterization of the patients to understand the underlying differences between the patients and the underlying disease biology. There's nothing in the data that currently suggests that ER96 would only work in a subgenetically defined subgroup of patients. Also, unfolded protein response pathways are a very general target, if you will, in neurodegeneration. So that also supports that view.

Nicola
49:32 - 49:38

In light of these results, what is your best-case scenario for getting the product to the market time-wise?

Unknown 1
49:40 - 50:16

That's a very good and important question, which we actually haven't commented on yet, and I won't comment on that either right now here. So the next step that we foresee is to run a phase two proof of concept study, hopefully starting or targeted to start during the next year. And it really depends on the efficacy signal that we might see in that study, which will then decide on the next step after the phase two. So I will not start speculating about the different options there.

Nicola
50:17 - 50:26

Okay. I think that concludes the Q&A session. A lot of really good questions. So there's a lot of enthusiasm among the audience. That's good.

Unknown 1
50:27 - 51:03

Thank you a ton. And I think this concludes our webcast for Phase One B top-line data. I want to emphasize that the data was really good. We were really happy with what we were achieving. And this gives us a great opportunity to go into phase two efficacy trials. Thank you for listening to us today, and I hope that you will follow our story going forward. Thanks a lot.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…